FLEXION THERAPEUTICS, INC. Inactive Instrument
Flexion Therapeutics, Inc.
Equities
FLXN
US33938J1060
Biotechnology & Medical Research
Presenter SpeechMartin Auster (Analysts)Okay, everybody. I'm Marty Auster. I'm the lead SMID C...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Flexion Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. It is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. It markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The Company's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.04% | 114B | |
| +11.36% | 104B | |
| -12.43% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -2.44% | 17.89B | |
| +8.11% | 14.28B | |
| +34.97% | 12.55B |
